<code id='A82DB15184'></code><style id='A82DB15184'></style>
    • <acronym id='A82DB15184'></acronym>
      <center id='A82DB15184'><center id='A82DB15184'><tfoot id='A82DB15184'></tfoot></center><abbr id='A82DB15184'><dir id='A82DB15184'><tfoot id='A82DB15184'></tfoot><noframes id='A82DB15184'>

    • <optgroup id='A82DB15184'><strike id='A82DB15184'><sup id='A82DB15184'></sup></strike><code id='A82DB15184'></code></optgroup>
        1. <b id='A82DB15184'><label id='A82DB15184'><select id='A82DB15184'><dt id='A82DB15184'><span id='A82DB15184'></span></dt></select></label></b><u id='A82DB15184'></u>
          <i id='A82DB15184'><strike id='A82DB15184'><tt id='A82DB15184'><pre id='A82DB15184'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:8

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In